Loading...
Proton-pump inhibitors (PPIs) are often used for long periods of time because of chronic conditions or risks. The safety of such use remains unclear.
To evaluate the safety of chronic PPI use, investigators analyzed safety data from two industry-funded prospective trials randomizing patients with gastroesophageal reflux disease (GERD) to PPI (omeprazole or esomeprazole) therapy or antireflux surgery (ARS). In the SOPRAN study, serious adverse events (SAEs) were assessed in 298 patients with median exposures of 12 years in the PPI group and 10 years in the ARS group. The LOTUS study had a similar design and involved 514 patients with median exposures of 5 years in both groups. In each study, results were as follows:
The rate of SAEs was simila…